GlassScriptPhysician profile
John G Booker
NPI 1720015373
$921.72
in general payments reported to CMS, 2019-2025
14 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $58.30 · 2021: $26.79 · 2022: $151 · 2023: $178 · 2024: $145 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.33 | 2019-2025 | Orilissa |
| Astellas Pharma US INC | $102.53 | 2022-2024 | Veozah |
| Avion Pharmaceuticals | $97.47 | 2019-2023 | Balcoltra |
| Shield Therapeutics INC | $82.17 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $79.68 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Organon LLC | $72.14 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $53.02 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $43.53 | 2019-2020 | |
| Minerva Surgical, INC | $34.43 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $33.91 | 2022 | |
| Smith+Nephew, INC. | $28.88 | 2022-2024 | Stravix |
| Integra Lifesciences Corporation | $19.62 | 2023 | Biodoptix, Biofix, Biodrestore |
| Pfizer INC. | $18.11 | 2023 | |
| Kci USA, INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Booker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.